Sung-Chul Jung, MD, PhD, is a physician-scientist and Professor of Biochemistry at the College of Medicine, Ewha Womans University in Seoul, South Korea. His research focuses on developing novel therapeutic strategies for genetic diseases and peripheral neuropathies, including enzyme replacement, cell therapy, and gene therapy. His work connects the study of disease mechanisms with the development of treatments for patients with inherited and acquired disorders.
Dr. Jung and his colleagues are advancing cell therapy approaches for peripheral nerve diseases, including Charcot-Marie-Tooth disease and diabetic peripheral neuropathy. He has collaborated with biopharmaceutical companies as a principal investigator, scientific advisor, and external director, supporting the investigation of therapeutic mechanisms of action and the advancement of preclinical and clinical development programs.
Beyond his academic research, Dr. Jung has held leadership roles in the oversight and management of national healthcare R&D programs. He brings a perspective that spans basic medical science, translational research, and national research funding and management. He previously served as President of the Korean Society of Inherited Metabolic Disease and participates in academic societies focused on biochemistry, molecular genetics, and regenerative medicine.
In 2018, Dr. Jung received a Presidential Citation from the Korean Government in recognition of his contributions to the advancement of bio-health R&D. He also serves as a review committee member of Korea’s National Committee for Advanced Regenerative Medicine and Biological Products. As a member of Liferna’s Scientific Advisory Board, Dr. Jung provides expertise in genetic disease biology, peripheral neuropathies, and translational development to support the advancement of the company’s regenerative medicine programs.